Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

Trial Profile

Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs JNJ 63871860 (Primary)
  • Indications Escherichia coli infections; Urinary tract infections
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 08 Sep 2017 Planned End Date changed from 31 Aug 2017 to 31 Aug 2020.
    • 13 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 07 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top